Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

[
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
[og_img]
https://www.investing.com/news/press-releases/pfizers-sasanlimab-combination-significantly-improves-eventfree-survival-in-bcgnaave-highrisk-nonmuscle-invasive-bladder-cancer-93CH-4005883


Investing.com